Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KROCUS: Fulzerasib + Cetuximab in previously untreated KRAS G12C-mutated NSCLC
NCT05756153Phase 2Completed
- Sponsor
- GenFleet Therapeutics
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of fulzerasib in non-small cell lung cancer (NSCLC), sponsored by GenFleet Therapeutics. Started Apr 2023; status: completed.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05756153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756153.